SCHEMBL24328918

SCHEMBL24328918

N#Cc1cccc2c(C[C@H](O)C(=O)O)c[nH]c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
NR3C1 P04150 1/20 0.47
PGR P06401 1/20 0.47
NR3C2 P08235 1/20 0.47
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
APAF1 O14727 1/20 0.40
POLB P06746 1/20 0.40
RECQL P46063 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MPO P05164 1/20 0.40
TSHR P16473 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
KMT2A Q03164 1/20 0.40
HIF1A Q16665 1/20 0.40
DYRK1A Q13627 5/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25166892 0.86 MAPT (0.58) SMN1; SMN2NR3C1PGRNR3C2KDM4E
SCHEMBL25166893 0.86 MAPT (0.58) SMN1; SMN2NR3C1PGRNR3C2KDM4E
SCHEMBL30778926 0.86 MAPT (0.58) SMN1; SMN2NR3C1PGRNR3C2KDM4E
SCHEMBL24328259 0.84 NR3C1 (0.47) SMN1; SMN2NR3C1PGRNR3C2KDM4E
SCHEMBL24328355 0.80 SMN1; SMN2 (0.61) SMN1; SMN2KDM4EMAPTAPAF1POLB
SCHEMBL28417401 0.80 SMN1; SMN2 (0.61) SMN1; SMN2NR3C1PGRNR3C2KDM4E
SCHEMBL28416704 0.80 SMN1; SMN2 (0.61) SMN1; SMN2KDM4EMAPTAPAF1POLB
SCHEMBL24328921 0.80 SMN1; SMN2 (0.61) SMN1; SMN2NR3C1PGRNR3C2KDM4E
SCHEMBL24301152 0.80 SMN1; SMN2 (0.61) SMN1; SMN2MPOSLC6A4TNF
SCHEMBL30024220 0.80 SMN1; SMN2 (0.61) SMN1; SMN2KDM4EMAPTAPAF1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
US-20230399297-A1 Novel Glutamine Analogs JACOBIO PHARMACEUTICALS CO., LTD (CN) 2023-12-14 US disclosed
WO-2022078416-A1 NOVEL GLUTAMINE ANALOGS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399297-A1 Novel Glutamine Analogs GLUL, GATD3, GLS SMN1; SMN2 3812/4885NR3C1 4561/4885PGR 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.